Hua Medicine (Shanghai) Ltd announced that it has raised $117.4 million in its combined series D and series E round of funding on March 26, 2018. The round included participation from new investors Blue Pool Capital Ltd., GIC Pte. Ltd., AVICT Global Holdings Limited, Adrian Cheng through K11 Investments, Ping An Ventures, Mirae Asset Financial Group, and certain healthcare funds managed by a leading United States investment management firm and returning investors Arch Venture Partners, L.P., Eight Roads Ventures China, Impresa Management LLC, Venrock, WuXi PharmaTech Corporate Venture Fund, a fund managed by 6 Dimensions Capital, Ally Bridge Group, Harvest Fund Management Co.

Ltd, and co-founders and management.